Formycon Ag

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Formycon Invites to Conference Call on 2025 Half-year Results and Announces Participation in International Investor Conferences in the 3rd Quarter of 2025

Formycon Successfully Completes Patient Enrollment for the Clinical Development of Its Keytruda(R) Biosimilar Candidate FYB206